Patents by Inventor William D. Shipe

William D. Shipe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10870630
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: December 22, 2020
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, William D. Shipe, Kenneth J. Leavitt, John M. Sanders, Deodial G. Guiadeen, Linda M. Suen, Thomas J. Greshock, Vanessa L. Rada
  • Publication number: 20200262826
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).
    Type: Application
    Filed: September 14, 2018
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Brendan M. Crowley, Peter J. Manley, William D. Shipe
  • Patent number: 10647727
    Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: May 12, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gregori J. Morriello, Lehua Chang, Ashley Forster, Richard Berger, Kausik K. Nanda, William D. Shipe
  • Publication number: 20190337910
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: March 20, 2017
    Publication date: November 7, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: BRENDAN M. CROWLEY, BRIAN T. CAMPBELL, JOSEPH L. DUFFY, THOMAS J. GRESHOCK, DEODIAL G. GUIADEEN, ANDREW JOHN HARVEY, BELINDA C. HUFF, KENNETH J. LEAVITT, VANESSA L. RADA, JOHN M. SANDERS, WILLIAM D. SHIPE, LINDA M. SUEN, IAN M. BELL
  • Publication number: 20190308945
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: October 30, 2017
    Publication date: October 10, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: BRENDAN M. CROWLEY, IAN M. BELL, ANDREW JOHN HARVEY, WILLIAM D. SHIPE, KENNETH J. LEAVITT, JOHN M. SANDERS, DEODIAL GUY GUIADEEN, LINDA M. SUEN, THOMAS J. GRESHOCK, VANESSA L. RADA
  • Patent number: 10160762
    Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: December 25, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, Michael P. Dwyer, Christopher J. Sinz, Deping Wang, Shawn J. Stachel, Daniel V. Paone, Ashley Forster, Richard Berger, Yili Chen, Yimin Qian, Shimin Xu, Chunmei Hu, William D. Shipe, Jianmin Fu, Zhigang Guo, Haitang Li, Yingjian Bo
  • Publication number: 20180162874
    Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: June 20, 2016
    Publication date: June 14, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gregori J. Morriello, Michael P. Dwyer, Lehua Chang, Yili Chen, Ming Wang, Ashley Forster, Richard Berger, Kausik k Nanda, Jaime L Bunda, William D Shipe
  • Publication number: 20180134712
    Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.
    Type: Application
    Filed: May 24, 2016
    Publication date: May 17, 2018
    Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.
    Inventors: Dong-Ming Shen, Michael P. Dwyer, Christopher J. Sinz, Deping Wang, Shawn J. Stachel, Daniel V. Paone, Ashley Forster, Richard Berger, Yilli Chen, Yimin Qian, Shimin Xu, Chunmel Hu, William D. Shipe, Jianmin Fu, Zhigang Guo, HAITANG LI, Yingjian Bo
  • Publication number: 20180030007
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Application
    Filed: October 9, 2017
    Publication date: February 1, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Thomas J. Greshock, Deodial G. Guiadeen, Andrew John Harvey, Belinda C. Huff, Kenneth J. Leavitt, Vanessa L. Rada, John M. Sanders, William D. Shipe, Linda M. Suen, Ian M. Bell
  • Patent number: 9840481
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: December 12, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Thomas J. Greshock, Deodial G. Guiadeen, Andrew John Harvey, Belinda C. Huff, Kenneth J. Leavitt, Vanessa L. Rada, John M. Sanders, William D. Shipe, Linda M. Suen, Ian M. Bell
  • Publication number: 20170275260
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Application
    Filed: March 20, 2017
    Publication date: September 28, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: BRENDAN M. CROWLEY, BRIAN T. CAMPBELL, JOSEPH L. DUFFY, THOMAS J. GRESHOCK, DEODIAL G. GUIADEEN, ANDREW JOHN HARVEY, BELINDA C. HUFF, KENNETH J. LEAVITT, VANESSA L. RADA, JOHN M. SANDERS, WILLIAM D. SHIPE, LINDA M. SUEN, IAN M. BELL
  • Patent number: 9266881
    Abstract: The present invention is directed to triazolopyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: February 23, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James C. Barrow, Christopher D. Cox, Mark B. Nolt, William D. Shipe
  • Patent number: 9051299
    Abstract: The present invention is directed to imidazolyl methyl piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: June 9, 2015
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Craig W. Lindsley, William D. Shipe
  • Publication number: 20150051248
    Abstract: The present invention is directed to imidazolyl methyl piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
    Type: Application
    Filed: March 26, 2013
    Publication date: February 19, 2015
    Inventors: Craig W. Lindsley, William D. Shipe
  • Publication number: 20140343053
    Abstract: The present invention is directed to triazolopyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: November 9, 2012
    Publication date: November 20, 2014
    Applicant: Merck Sharpe & Dohme Corp.
    Inventors: James C. Barrow, Christopher D. Cox, Mark B. Nolt, William D. Shipe
  • Patent number: 8785467
    Abstract: The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: July 22, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher D. Cox, Izzat T. Raheem, William D. Shipe, Cory R. Theberge
  • Publication number: 20130203756
    Abstract: The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: October 24, 2011
    Publication date: August 8, 2013
    Inventors: Jamie L. Bunda, Christopher D. Cox, Vadim Y. Dudkin, Hannah D. Fiji, Michael J. Kelly, Mark E. Layton, Joseph E. Pero, William D. Shipe, Justin T. Sheen
  • Patent number: 8501773
    Abstract: The present invention is directed to 4-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: August 6, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James C. Barrow, Craig W. Lindsley, William D. Shipe, Zhiqiang Yang, David Wisnoski
  • Publication number: 20130158056
    Abstract: The present invention is directed to 2-alkoxy pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: September 26, 2011
    Publication date: June 20, 2013
    Inventors: Christopher D. Cox, Izzat T. Raheem, William D. Shipe, Cory R. Theberge
  • Patent number: 8389545
    Abstract: The present invention is directed to quinolone compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders, and to novel M1 receptor positive allosteric modulator compounds of formulae (II) to (VIII). The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases in which the M1 receptor is involved.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: March 5, 2013
    Assignee: Merck, Sharp & Dohme, Corp.
    Inventors: William D. Shipe, Craig Lindsley, David Hallett